查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495993

C 反應蛋白 (CRP) 檢測的全球市場：2024-2029 年預測

Global C-Reactive Protein (CRP) Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

C反應蛋白（CRP）檢測市場預計到2022年將達到19.53億美元，預測期內複合年成長率為2.43%，預計到2029年市場總規模將達到22.93億美元。

CRP測試是測量體內CRP濃度的測試。體內 C 反應蛋白水平升高是由發炎引起的。這種蛋白質是在肝臟產生的。使用 C 反應蛋白檢測來識別和追蹤發炎疾病和感染疾病。 C反應蛋白測試包括癌症、心血管疾病、關節炎等。此測試可評估您是否有心臟病發作或中風的風險。

心血管疾病（CVD）變得越來越普遍，檢測也變得越來越複雜，因此這個市場正受到這些因素的推動。根據世界衛生組織的報告，CVD 每年導致約 1,790 萬人死亡。這個市場有很多機會，包括擴大這些測試的應用、就地檢驗、增加人口覆蓋率以及提高醫療保健意識，特別是在開發中國家。

由於政府向學術研究機構和個人提供的資金增加，預計該市場也會成長。此外，世界衛生組織和美國國立衛生研究院等國際組織旨在預防和治療癌症和心血管疾病等慢性疾病的各種措施也有望推動市場成長。

在全球範圍內，由於發炎疾病盛行率的上升、女性子宮內膜異位症盛行率的增加以及診斷檢測技術的進步，C反應蛋白檢測市場將會成長。許多慢性疾病，包括狼瘡、潰瘍性大腸炎和類風濕性關節炎，被認為是由慢性發炎引發的。

根據美國疾病管制與預防中心 (CDC) 2016 年的報告，預計到 2040 年，大約 7,800 萬 (26%) 18 歲及以上的美國成年人將患有關節炎。此外，該市場的成長也因缺乏公眾意識而受到挑戰。

市場促進因素：

  • 心血管疾病的增加預計將推動 C 反應蛋白 (CRP) 檢測市場的成長。

鑑於心血管疾病的高盛行率，迫切需要開發快速、準確的診斷方法。因此，CRP 可用於檢測由於動脈粥狀硬化的發展而導致的 CVD，其中膽固醇沉積在血管壁內並引起發炎。因此，心血管疾病患者的 CRP 水平較高。

因此，這些 CRP檢測法可以高靈敏度檢測低 CRP 水平。隨著心血管疾病變得越來越普遍，研究人員可能會繼續評估 CRP 對心血管疾病的影響。據世界心臟聯合會稱，心臟疾病是全世界死亡的主要原因。據估計，每年有380萬名男性和340萬名女性死於心臟疾病。 80%以上的死亡發生在低收入和中等收入國家。

此外，根據美國心臟協會 2019 年的資料，美國每年約有 356,000 例院外心臟麻痹，其中 90% 是致命的。這就是臨床醫生擴大進行 CRP 檢測的原因。因此，這些因素共同導致心血管疾病領域在預測期內穩定成長。

許多研究和開發計劃是由大學和其他組織進行的。例如，香港大學的研究小組開發了一種即時、靈活的感測裝置，可以直接測量CRP血液水平。使用該感測器，發炎測試速度比正常情況快 30 倍。此類事件是促進 CRP 檢測市場成長的主要因素。

  • 定期 CRP 測試的技術改進預計將推動市場成長。

隨著時間的推移，CRP 已發展成為一種用於確定全身發炎疾病的靈活診斷工具。奈米材料和電分析化學的進步導致了具有更高靈敏度和特異性的 CRP 測試的創建。 CRP 測試已發展為使用現代電化學生物感測器的基於 CRP 的酵素測試，並逐漸取代經典的抗原抗體交互作用。

基於ZnS奈米顆粒、金屬氧化物半導體場效電晶體/雙極電晶體、適配體、矽奈米線、垂直流免疫免疫檢測、場發射發射器和其他奈米材料的電化學感測器具有高靈敏度和可攜式，用於檢測的開發。

多學科方法的未來進步應該能夠在更短的時間內實現超靈敏的 CRP 水平分析。因此，用於診斷全身發炎疾病的CRP檢測方法可能會被更多人使用。有助於創建感測平台的新 CRP 識別化學物質和材料也為 CRP 測試市場提供了許多前景。

市場限制因素：

  • 高成本和低社會意識可能會阻礙市場成長。

然而，CRP檢測設備價格昂貴。高成本在指定對市場起到限制作用。此外，該領域合格專業人員的缺乏也會在一定時期內阻礙CRP檢測市場的發展。此外，大眾對 CRP 檢測的認知較低以及診斷某些疾病的特異性較低預計也會抑制市場成長。

主要進展

  • 2022 年 11 月 - ProciseDx 的 ProciseDx 裝置和 C 反應蛋白 (CRP)檢測法可在 5 分鐘內定量測量患者血清中的 CRP 濃度。該公司還預計 FDA 會批准其他測試。 ProciseDx 已獲得 CE 標誌，並在歐洲啟動了四項消化器官系統測試，已安裝 30 台機器，50 個設施正準備實施。在美國，ProciseDx 提交了測量兩項 TDM 測試的從頭申請，Procise IFX 測量Infliximab（Remicade和生物學名藥），Procise ADL 測量Adalimumab（Humira和生物學名藥）。
  • 2022 年 1 月 - LumiraDx 是下一代照護現場，獲得 C 反應蛋白 (CRP) 測試的 CE 標誌。該測試是一種小型、攜帶式、全自動微流體免疫檢測，可在 4 分鐘內定量測量 CRP。此測試有助於檢測和評估感染疾病和發炎，CRP水平高表明有呼吸道感染疾病症狀的患者需要抗生素治療，而CRP水平正常或低值表明感染疾病或自限性感染疾病，不需要抗生素。它可以在基層醫療、社區護理、患者家中和醫院急診護理中靠近患者使用。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球 C 反應蛋白 (CRP) 測試市場：按類型

  • 介紹
  • 免疫比濁法
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • ELISA
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 化學冷光
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 光譜分析
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章 C 反應蛋白 (CRP) 測試的全球市場：按應用分類

  • 介紹
  • 心血管疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 癌症
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 類風濕性關節炎
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 狼瘡
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球C 反應蛋白 (CRP) 測試市場：依最終用戶分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 診斷中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球C反應蛋白（CRP）檢測市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Medix Biochemica
  • Biolab
  • Abbott
  • Novus Biologicals, LLC
  • Cenogenics Corporation
  • Salimetrics, LLC
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific
  • Beckman Coulter, Inc.
  • Trinity Biotech
簡介目錄
Product Code: KSI061611697

The C-Reactive Protein (CRP) testing market was valued at US$1.953 billion in 2022 and is expected to grow at a CAGR of 2.43% over the forecast period to reach a total market size of US$2.293 billion by 2029.

Tests for C-reactive protein (CRP) measure levels of this protein in the body. An increase in C-reactive protein levels in the body can be attributed to inflammation. The liver produces this protein. Inflammatory diseases and infections are identified and tracked by C-reactive protein tests, which include cancers, cardiovascular disease, arthritis, etc. The tests estimate whether someone is at risk of having a heart attack or stroke.

Cardiovascular diseases (CVDs) have become more prevalent, and as tests are becoming more complex, this market is being driven by these factors. As reported by the WHO, CVDs kill about 17.9 million people each year. Numerous opportunities exist in the market, including the growing application of these tests, point-of-care testing, increased population coverage, and increased healthcare awareness, particularly in developing countries.

The market is also expected to grow due to increased funds provided by the government to academic research institutions and individuals. Market growth is further anticipated to be supported by various initiatives by international organizations, including WHO and NIH, that aim to prevent and treat chronic disorders such as cancer and cardiovascular diseases.

Globally, the market for C-reactive protein tests will grow because of the rising prevalence of inflammatory disorders, the increasing prevalence of endometriosis in women, and technological advancements in diagnostic tests. A large number of chronic diseases, including lupus, ulcerative colitis, rheumatoid arthritis, and others, are thought to be triggered by chronic inflammation.

According to the Centers for Disease Control and Prevention (CDC) 2016 report, it is estimated that by 2040, approximately 78 million (26%) of US adults aged 18 and up will have arthritis. Furthermore, this market's growth would be challenged by the lack of public awareness.

Market Drivers:

  • An increase in cardiovascular disease is anticipated to surge the C-reactive protein (CRP) testing market growth.

It is urgently necessary to develop a quick and accurate method for diagnosing cardiovascular diseases, given their high prevalence. CRP can, therefore, be used to detect CVD due to the development of atherosclerosis, in which cholesterol is deposited inside blood vessel walls, leading to inflammation. As a result, CRP levels are higher in patients with cardiovascular disease.

Consequently, these CRP assays can detect low CRP levels, which are sensitive. Because cardiovascular diseases are increasingly prevalent, researchers are likely to pursue evaluations of CRP for cardiovascular disorders. According to the World Heart Federation, coronary heart disease is the leading cause of death in the world. There are an estimated 3.8 million males and 3.4 million females who die of coronary heart disease every year. More than 80% of deaths occur in low- and middle-income countries.

Additionally, approximately 356,000 cardiac arrests occur in the U.S. outside of hospitals every year, of which 90% are fatal, according to data from the American Heart Association 2019. It is for this reason that clinicians are increasingly implementing CRP testing. Hence, these factors combined are causing the cardiovascular diseases segment to grow at a steady pace over the forecast period.

Many research and development projects are conducted by universities and other organizations. For example, a group of researchers from the University of Hong Kong has developed a real-time, flexible sensing device that can directly measure CRP blood levels. With this sensor, inflammation testing is 30 times faster than usual. Incidents such as these are a major factor contributing to the C-reactive protein testing market growth.

  • Technological improvements in regular CRP tests are expected to propel the market growth.

Over time, CRP has developed into a flexible diagnostic tool for determining systemic inflammatory disorders. Advances in nanomaterials and electroanalytical chemistry have led to the creation of CRP tests with higher sensitivity and specificity. CRP testing has advanced to include CRP-based enzymatic tests using modern electrochemical biosensors, gradually replacing classical antigen-antibody interactions.

Electrochemical sensors are used in the development of a highly sensitive, portable detection system based on ZnS nanoparticles, metal-oxide-semiconductor field-effect transistor/bipolar junction transistor, aptamer, silicon nanowire, vertical flow immunoassay, field emission transmitter, and other nanomaterials.

Ultrasensitive CRP level analysis should be possible in much less time with future advancements in multidisciplinary approaches. Thus, CRP testing methods for diagnosing systemic inflammatory illnesses would be used by more individuals. New CRP identification chemicals and materials that facilitate the creation of sensing platforms also present a lot of prospects in the CRP testing market.

Market Restraints:

  • High cost and low public awareness could hinder market growth.

CRP testing instruments, however, are expensive. High costs will constrain the market during the given period. The lack of qualified professionals in the field will also hinder the market for CRP tests during the given period. In addition, low public awareness about the CRP test, as well as its low specificity in diagnosing a particular disease, are expected to restrain the market's growth.

Key Developments:

  • November 2022- ProciseDx received FDA clearance for its ProciseDx instrument and C Reactive Protein (CRP) assay, which provides quantitative determination of CRP levels in patient serum in less than 5 minutes. The company expects FDA clearances for additional tests. ProciseDx has already obtained CE Marks and launched four gastroenterology tests in Europe, with 30 instruments installed and 50 sites working towards implementation. In the US, ProciseDx has submitted De Novo applications for two TDM tests, Procise IFX measures infliximab (Remicade(R) and biosimilars), and Procise ADL measures adalimumab (Humira(R) and biosimilars).
  • January 2022- LumiraDx, a next-generation point-of-care diagnostics company, achieved CE Marking for its C-reactive protein (CRP) Test. The test is a small, portable, fully automated microfluidic immunoassay that provides quantitative CRP determination within four minutes. It helps detect and evaluate infection and inflammation, with high CRP levels indicating antibiotic treatment in patients with respiratory infection symptoms, while normal or low CRP levels indicate viral or self-limiting infections that don't require antibiotics. It can be used at the patient's side in primary and community care, patient homes, and hospital emergency care settings.

Market Segmentation:

By Type

  • Immunoturbidimetric method
  • ELISA
  • Chemiluminescence
  • Spectrometry

By Application

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Lupus
  • Others

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres

By Geography

  • North America
  • United States
  • Canada
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Immunoturbidimetric method
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. ELISA
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Chemiluminescence
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Spectrometry
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cardiovascular Diseases
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Cancer
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Lupus
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Centres
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL C-REACTIVE PROTEIN (CRP) TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Medix Biochemica
  • 10.2. Biolab
  • 10.3. Abbott
  • 10.4. Novus Biologicals, LLC
  • 10.5. Cenogenics Corporation
  • 10.6. Salimetrics, LLC
  • 10.7. Randox Laboratories Ltd
  • 10.8. Thermo Fisher Scientific
  • 10.9. Beckman Coulter, Inc.
  • 10.10. Trinity Biotech